MktsMarkets

Cartesian Therapeutics, Inc.
NASDAQ: RNACKey statistics
RNAC News
Stories mentioning RNAC from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 400.00 | (836.00) | 0.00 | 33,271 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 19,463 | 14,689 | 13,802 | 14,869 | 14,674 | 11,306 | 11,400 | 12,661 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 26,577 | 79,586 | 21,518 | 22,109 | 22,989 | 25,972 | 17,962 | 19,688 |
| Operating Income (Loss) | (26,499) | (78,639) | (21,066) | (21,811) | (21,889) | (26,731) | (17,575) | 13,757 |
| Interest Income | 1,026 | 2,015 | ||||||
| Interest Expense | ||||||||
| Other Expense | (3.00) | (2,005) | 0.00 | (5.00) | 0.00 | (444.00) | 250.00 | 292.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (39,182) | (92,576) | (35,902) | 15,886 | (17,710) | (10,253) | (24,183) | 13,836 |
| Earnings Per Share (Basic) | (1.46) | (3.56) | (1.38) | 0.51 | (0.68) | (0.59) | (1.13) | 0.58 |
| Earnings Per Share (Diluted) | (1.46) | (3.56) | (1.38) | 0.50 | (0.68) | (0.59) | (1.13) | 0.54 |
| Weighted Average Shares Outstanding (Basic) | 26,855 | 25,973 | 26,003 | 25,980 | 25,903 | 17,277 | 21,471 | 16,723 |
| Weighted Average Shares Outstanding (Diluted) | 26,855 | 25,973 | 26,003 | 26,447 | 25,903 | 17,358 | 21,471 | 17,791 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RNAC
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a stock listed on the Nasdaq Stock Market under the ticker symbol RNAC. It last traded at $6.14 (Nov 20, 2026, 9:30 AM ET), up 4.2% on the day. That gives Cartesian Therapeutics a market capitalisation of $187.0M.
Over the past 52 weeks RNAC has traded between $5.60 and $11.00.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $39.2M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | $0 | -$39.2M |
| Dec 31, 2025 | $0 | -$92.6M |
| Sep 30, 2025 | $0 | -$35.9M |
| Jun 30, 2025 | $0 | $15.9M |
From Cartesian Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…